<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465464</url>
  </required_header>
  <id_info>
    <org_study_id>Taiho132150</org_study_id>
    <nct_id>NCT01465464</nct_id>
  </id_info>
  <brief_title>Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <acronym>ORIENTAL</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the overall survival (OS) for Orantinib in
      combination with transcatheter arterial chemoembolization (TACE) versus placebo in
      combination with TACE in patients with unresectable hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, double-blind, placebo-controlled phase III trial of
      Orantinib administered in combination with TACE in patients with unresectable HCC.

      Patients will be randomly assigned (1:1) to receive TACE given in combination with either
      Orantinib (200 mg orally, twice per day) or placebo.

      ORIENTAL:ORantinib InvEstigatioN on TAce combination triaL.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>The time from the date of enrollment to the date of death from any cause, assessed up to three years after randomizationof the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Transcatheter Arterial Chemoembolization (TACE) Failure</measure>
    <time_frame>The time from the date of enrollment to the date of event for TACE discontinuation, assessed up to three years after randomizationof the last patient</time_frame>
    <description>Patients should not receive additional TACE therapy in this study after meeting any of the following conditions, at the Investigator's discretion.
The patient develops an intra-hepatic lesion that is uncontrolled by serial TACE
Deterioration in arterial pathways to treat HCC that makes additional TACE impossible
Severe vascular invasion occurs that makes additional TACE impossible
Extra hepatic spread considered relevant to life expectancy that requires another treatment modality for HCC
Liver function at grade Child-Pugh class C lasting for 28 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">888</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Orantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orantinib (TSU-68)</intervention_name>
    <description>200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
    <arm_group_label>Orantinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet was administered orally twice per day after meals, morning and evening.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be diagnosed as HCC.

          -  Patients has no indications for treatment with curative hepatic resection or curative
             percutaneous local therapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

          -  Patients are able to receive oral medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>November 4, 2018</results_first_submitted>
  <results_first_submitted_qc>August 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orantinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Orantinib</title>
          <description>Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="444"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing treatment at cutoff date</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Orantinib</title>
          <description>Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="444"/>
            <count group_id="B2" value="444"/>
            <count group_id="B3" value="888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="444"/>
                    <measurement group_id="B2" value="444"/>
                    <measurement group_id="B3" value="888"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival(OS)</title>
        <time_frame>The time from the date of enrollment to the date of death from any cause, assessed up to three years after randomizationof the last patient</time_frame>
        <population>When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.
Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Orantinib</title>
            <description>Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival(OS)</title>
          <population>When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.
Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="946.0" lower_limit="807.0" upper_limit="1050.0"/>
                    <measurement group_id="O2" value="984.0" lower_limit="864.0" upper_limit="NA">The upper limit of median OS didn't reach.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.878</ci_lower_limit>
            <ci_upper_limit>1.352</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Transcatheter Arterial Chemoembolization (TACE) Failure</title>
        <description>Patients should not receive additional TACE therapy in this study after meeting any of the following conditions, at the Investigator's discretion.
The patient develops an intra-hepatic lesion that is uncontrolled by serial TACE
Deterioration in arterial pathways to treat HCC that makes additional TACE impossible
Severe vascular invasion occurs that makes additional TACE impossible
Extra hepatic spread considered relevant to life expectancy that requires another treatment modality for HCC
Liver function at grade Child-Pugh class C lasting for 28 days</description>
        <time_frame>The time from the date of enrollment to the date of event for TACE discontinuation, assessed up to three years after randomizationof the last patient</time_frame>
        <population>When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.
Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Orantinib</title>
            <description>Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Transcatheter Arterial Chemoembolization (TACE) Failure</title>
          <description>Patients should not receive additional TACE therapy in this study after meeting any of the following conditions, at the Investigator's discretion.
The patient develops an intra-hepatic lesion that is uncontrolled by serial TACE
Deterioration in arterial pathways to treat HCC that makes additional TACE impossible
Severe vascular invasion occurs that makes additional TACE impossible
Extra hepatic spread considered relevant to life expectancy that requires another treatment modality for HCC
Liver function at grade Child-Pugh class C lasting for 28 days</description>
          <population>When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC.
Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="728.0" lower_limit="604.0" upper_limit="813.0"/>
                    <measurement group_id="O2" value="602.0" lower_limit="539.0" upper_limit="724.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the first treatment to 30 days after the last treatment</time_frame>
      <desc>Main treatment discontinuation criteria
The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC
Patient has unacceptable/intolerable toxicities
Patient can not take both enhanced CT and enhanced MRI of the abdomen any more
Patient wishes to discontinue the treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Orantinib</title>
          <description>Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE, version 4.02</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Paroxysmal supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele cord</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cataract aggravated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Retinal macroaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute gastric ulcer with haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Esophageal varices hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric varices bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastroesophageal varices hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ischemia bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ischemic enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Right upper quadrant pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ulcer duodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Multi organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Weakness generalised</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Biliary fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dilatation intrahepatic duct acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Haemobilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic function disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Obstructive jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Acute pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cellulitis of foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cryptococcal pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intra-abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Periodontal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulpitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spontaneous bacterial peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fracture of lateral malleolus, closed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Polytraumatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Post embolization syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>CRP increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Liver biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spleen scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>WBC decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gout aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Inappetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Inappetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cervical disc herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pain in thigh</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pseudogout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Wrist pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Avascular necrosis femoral head</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bone metastases</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Brain metastases</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cancer of descending colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma non-resectable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Liver carcinoma ruptured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lung metastases</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spinal metastases</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tumor necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tumor rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the gastrooesophageal junction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of spinal cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cecal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Inverting papilloma of the nasal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of cheek mucosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tumour embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Numbness of lower extremities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Orientation disturbed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Chronic cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal variceal haemorrhage prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Induced abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oesophageal variceal ligation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Obstructive arteriosclerosis of lower extremities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE, version 4.02</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="443" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="436" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="284" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="223" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>ALP increased</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>CRP increased</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taiho Pharmaceutical Co., Ltd.</name_or_title>
      <organization>Clinical Trial Registration Contact</organization>
      <email>toiawase@taiho.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

